UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509

Cancer discovery, 2013-09, Vol.3 (9), p.1020-1029

2013

Volltextzugriff (PDF)

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Breast cancer research : BCR, 2009-01, Vol.11 (5), p.R77-R77, Article R77

2009

Volltextzugriff (PDF)

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2009-08, Vol.27 (22), p.3584-3590

2009

Volltextzugriff (PDF)

Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3525-3530

2013

Volltextzugriff (PDF)

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2014-01, Vol.32 (2), p.76-82

2014

Volltextzugriff (PDF)

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2009-09, Vol.27 (25), p.4068-4075

2009

Volltextzugriff (PDF)

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3743-3748

2008

Volltextzugriff (PDF)

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model

Cancer research (Chicago, Ill.), 2008-07, Vol.68 (14), p.5519-5523

2008

Volltextzugriff (PDF)

Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3763-3769

2008

Volltextzugriff (PDF)

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10), p.e003476

2021

Volltextzugriff (PDF)

Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer

Journal of clinical oncology, 2005-03, Vol.23 (7), p.1439-1446

2005

Volltextzugriff (PDF)

Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell Tumors

Journal of clinical oncology, 2004-10, Vol.22 (19), p.3868-3876

2004

Volltextzugriff (PDF)

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

JNCI : Journal of the National Cancer Institute, 2011-05, Vol.103 (9), p.763-773

2011

Volltextzugriff (PDF)

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

The New England journal of medicine, 2007-01, Vol.356 (2), p.115-124

2007

Volltextzugriff (PDF)

Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapy–Kidney Symptom Index—Disease-Related Symptoms Scale

Value in health, 2009-06, Vol.12 (4), p.580-586

2009

Volltextzugriff (PDF)

A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.TPS708-TPS708

2018

Volltextzugriff (PDF)

Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10052-10052

2020

Volltextzugriff (PDF)

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1965-1971

2023

Volltextzugriff (PDF)

Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4

Blood, 2012-08, Vol.120 (5), p.1095

2012

Volltextzugriff (PDF)

Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4

Blood, 2012-08, Vol.120 (5), p.1095-1106

2012

Volltextzugriff (PDF)

Treatment of Growing Teratoma Syndrome

The New England journal of medicine, 2009-01, Vol.360 (4), p.423-424

2009

Volltextzugriff (PDF)

Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS11082-TPS11082

2017

Volltextzugriff (PDF)

SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.6569-6569

2020

Volltextzugriff (PDF)

PCA3 upregulation in prostate cancer: Analysis in a cohort of 497 subjects from TCGA

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e16578-e16578

2017

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(52)
Buchkapitel
(1)

Sprache

Englisch
(53)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Humans
(23)
Male
(20)
Oncology
(18)
Middle Aged
(14)
Tumors
(13)
Aged
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Disease-Free Survival
(9)
Indoles - Adverse Effects
(9)
Pyrroles - Adverse Effects
(9)
Adult
(8)
Aged, 80 And Over
(8)
Carcinoma, Renal Cell - Drug Therapy
(8)
Female
(8)
Indoles - Administration & Dosage
(8)
Kidney Neoplasms - Drug Therapy
(8)
Kidney Neoplasms - Pathology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model

Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study

Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer

Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell Tumors

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapy–Kidney Symptom Index—Disease-Related Symptoms Scale

A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy

Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4

Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4

Treatment of Growing Teratoma Syndrome

Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma

SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study

PCA3 upregulation in prostate cancer: Analysis in a cohort of 497 subjects from TCGA

Suchergebnisse filtern